Shamonda Virus: The First Human Case, Explained

Educational information only. This guide explains published research and official health-agency statements about Shamonda virus. It is not medical advice, and it does not diagnose or recommend treatment for any individual. If you are unwell, or you care for livestock and are concerned about an animal, contact a qualified healthcare professional or a veterinarian and follow your country’s current guidance.

Read the companion guide: For the expert deep-dive — virology, genome segments, diagnostics and comparison with related viruses — see the Tier 2 guide: Shamonda Virus, Deep Dive: Virology, Vectors, Diagnostics

What is Shamonda virus?

Shamonda virus (abbreviated SHAV) is a virus that, for sixty years, was known only as an animal pathogen. It belongs to the genus Orthobunyavirus, in the family Peribunyaviridae, within a cluster of related viruses called the Simbu serogroup. Its closest well-known relative is Schmallenberg virus, which caused a major livestock epidemic in Europe in 2011. Until October 2026, Shamonda virus had never been documented in a human being.

That changed in France. In October 2026, French health authorities reported the first documented human infection with Shamonda virus, in a patient who died. The case matters not because it signals an imminent threat to the general public — every authority that has commented on it says the opposite — but because it rewrites a long-standing assumption. Until this case, Shamonda virus was considered non-transmissible to humans, despite decades of circulation among animals in Africa and Asia. A virus that was filed under “animals only” has now, once, crossed into a person. Understanding what happened, and what it does and does not prove, is the purpose of this guide.

A livestock virus with a sixty-year history

Shamonda virus was first isolated from cattle in Nigeria in 1965. From the early 2000s onwards, it was identified in other parts of Africa and in Asia, including Japan, where it re-emerged in cattle in the early 2000s. For decades it remained a sporadic, low-profile livestock virus: present in pastoral regions, occasionally detected, rarely making headlines.

Cattle are its main hosts, but infection has also been reported in sheep, goats, horses and alpacas. In adult animals, infection is usually mild and transient. The reported signs are fever, diarrhoea and a drop in milk production. The more serious consequences come when infection strikes during pregnancy: the virus can pass from mother to foetus, and it is associated with abortions and severe foetal malformations. Neurological signs have also been reported less commonly, and the virus has been detected in the central nervous system of horses showing neurological disorders.

The virus is spread by biting midges of the genus Culicoides — tiny, fly-like insects, only a few millimetres long, that feed on blood. Midges carry the virus from animal to animal. There is no evidence of direct animal-to-animal transmission through contact. Because midge activity follows the seasons, outbreaks of Simbu-group viruses tend to come in cycles that track the midge season, rising in warm months and falling as temperatures drop.

The European arrival in 2026

In 2026, Shamonda virus appeared in Europe for the first time. The World Health Organization (WHO) dates the first European detection to June 2026, in cattle in southern Germany and Switzerland. From there it spread quickly through western Europe’s livestock. French surveillance data illustrate the speed: as of 20 October 2026, the virus had been detected in cattle in 52 French departments, in sheep in two departments (Oise and Aveyron), and in a horse in the Hérault department.

The World Organisation for Animal Health (WOAH) reports that the 2026 European outbreaks are caused by two different variants of the virus, designated Shamonda virus Europe 1 (SHAV-EU1) and Shamonda virus Europe 2 (SHAV-EU2). WOAH is explicit that information on these variants is still evolving: their epidemiology, full geographic distribution, pathogenicity, long-term impact and zoonotic potential are all incompletely characterised, and even their precise characterisation and nomenclature are still being defined. In other words, scientists are still working out exactly what arrived in Europe, and how it differs from the virus that circulated in Africa and Asia for decades.

The first human case: what actually happened

On 7 October 2026, French health authorities were notified of a case of Shamonda virus infection in a severely immunocompromised patient who was being treated for a serious neurological condition at the Hospices Civils de Lyon, a major hospital in Lyon, and who subsequently died. Initial investigations detected the virus in several biological samples, confirming the infection. The case was publicly announced on 22 October 2026 by France’s health and agriculture ministries, and the WHO confirmed it as the first documented human case globally.

Three points about this case need to be stated precisely, because they are easy to blur in retellings.

First, the patient was exceptionally vulnerable. French authorities describe the infection as an exceptional case in a severely immunocompromised patient hospitalised for a serious medical condition, and they attribute the detection partly to the in-depth microbiological investigations carried out at the Lyon hospital. This was not a healthy person who fell ill after a midge bite; it was a person whose immune defences were already severely weakened.

Second, the link between the virus and the patient’s death is not yet proven. French authorities said the neurological complications observed before death were very likely linked to the infection, based on preliminary findings. But both the European Centre for Disease Prevention and Control (ECDC) and WOAH stress that investigations are still under way into whether the virus caused or contributed to the death. The honest formulation is: the virus was present, neurological complications were very likely linked to it, and the precise contribution to the death is still being investigated.

Third, the route of infection is a leading hypothesis, not a confirmed fact. The leading hypothesis is that the patient was infected through the bite of an infected Culicoides midge in eastern France, where the virus had been circulating among animals during spring and summer 2026. French investigators are still exploring other possible sources, including the patient’s environment, recent travel, and any exposure to animals or insect vectors. The exact midge species involved has not been identified; the WHO notes that further studies are needed to establish which arthropod species are involved in transmission.

What are the symptoms?

Here, honesty requires a short answer: in humans, we do not know. There has been exactly one documented human case, in a patient who was already seriously ill, so there is no human symptom profile to describe. The WHO states plainly that, with only one case reported, information on the disease in humans remains limited. In this case, the patient was already seriously ill and experienced additional brain-related symptoms that were considered linked to the virus.

What can be said is what the virus does in animals: fever, diarrhoea, reduced milk production, and, in pregnancy, abortions and foetal malformations, with neurological signs reported less commonly. None of that can be transferred to humans as a symptom list. Anyone who tells you the “symptoms of Shamonda virus in humans” as a settled list is going beyond the evidence. The single case suggests that, in a severely immunocompromised person, the virus can be associated with neurological complications. Whether it causes fever or other symptoms in humans, what its incubation period is, and whether healthy people would notice anything at all, are all unknown.

How does it spread — and can it spread between people?

On current evidence, Shamonda virus spreads through the bites of Culicoides midges. It is not known to transmit directly from animal to animal, other than from mother to foetus during pregnancy. Critically, no human-to-human transmission has been identified. France’s public health agency, Santé publique France, states that to date there is no evidence of human-to-human transmission or a health risk to the general population, and the French ministries’ joint statement said no health risk to the general public had been identified at this time.

That assessment has a seasonal logic behind it as well. The WHO has noted that the transmissibility of midge-borne viruses generally declines during the cooler months of the year, as midge activity falls. The human case emerged at the end of the 2026 midge season, not at its start.

None of this is a guarantee. It is an assessment based on one case, a virus family whose relatives have not spread between people, and a vector that is seasonal. If further human cases appear, the assessment will change, and this guide should be updated.

Is there a treatment or a vaccine?

No. The WHO states that there are currently no treatments or vaccines for Shamonda virus, and WOAH states that there are no commercially available vaccines against it. Care for the single human case was supportive care for a seriously ill patient, not a virus-specific treatment. This is one reason surveillance matters more than medicine here: with no drug and no vaccine, the only tools are detection, vector awareness and monitoring.

There is a related question worth answering, because it comes up whenever a livestock virus makes news: does immunity to the related Schmallenberg virus protect against Shamonda? According to Germany’s Friedrich-Loeffler-Institut, cited by WOAH, there appears to be little cross-protection from existing immunity to Schmallenberg virus — but the potential impact of that finding is unknown. In plain terms: herds that have met Schmallenberg should not be assumed to be protected against Shamonda.

How is it detected?

In animals, diagnosis requires laboratory testing, because the signs resemble those of other diseases. WOAH lists the methods in use: pan-Simbu PCR, a specific RT-PCR targeting the virus’s S genome segment, sequencing and multi-segment screening of the M and L segments, commercial real-time RT-PCR kits available in Europe, and serum neutralisation tests that can detect antibodies and help distinguish Shamonda from other Simbu-group viruses. Suitable samples include blood, serum from animals in the acute phase of infection, and brain and spleen tissue from aborted foetuses.

Human diagnosis is newer and less standardised. France’s National Reference Center for Arboviruses is working to improve biological diagnostic methods so the virus can be detected in humans, and full-genome sequencing of the virus from the patient is being compared with circulating animal strains to trace the source of infection. That comparison — patient virus against animal virus — is one of the most important investigations still under way, because it may confirm or revise the midge-bite hypothesis.

Prevention: what can actually be done?

There is no Shamonda-specific guidance for the general public, because there is no identified risk to the general public. What exists is vector control, aimed at livestock, and general midge-bite avoidance, which applies to many insect-borne diseases at once.

WOAH’s recommended measures for reducing infection risk in animals include physical barriers such as fine mesh screens and double-door entry-exit systems for animal housing, reducing or eliminating vector breeding sites, vector surveillance and control around buildings, using insect repellents during animal transport, and transporting animals during periods of low vector activity. For people spending time outdoors where midges are active, the standard precautions are covering exposed skin, using an insect repellent, and avoiding peak midge activity where practical. These are general precautions, not guarantees, and they are not a response to a demonstrated human risk from Shamonda specifically.

For farmers and veterinarians, the practical steps are surveillance-shaped: include Shamonda infection in the differential diagnosis of congenital malformations, stillbirths and reproductive disorders in susceptible species, and report suspected cases so that the picture of where the virus is, and what it is doing, keeps improving. WOAH encourages countries to report occurrences voluntarily, precisely because the virus is not a listed disease and is not formally recognised as an emerging disease under its Terrestrial Animal Health Code.

What scientists still don’t know

The list of unknowns is unusually long, and it is the most important part of this story:

• Whether Shamonda virus caused the patient’s death. The link to neurological complications is described as very likely, but the contribution to death is still under investigation.
• How the patient was infected. A midge bite in eastern France is the leading hypothesis, not a confirmed route, and the exact vector species is unknown.
• What the disease looks like in humans. One case in a severely immunocompromised patient cannot define a symptom profile, an incubation period, or a severity range.
• Whether healthy people can be infected at all. No human-to-human transmission has been identified, and no risk to the general public has been identified — but absence of evidence from a single case is not proof of impossibility.
• What the European variants are. SHAV-EU1 and SHAV-EU2 are still being characterised; their full teratogenic effects, pathogenicity and zoonotic potential are unknown.
• Why Europe, why now. How a virus that circulated for decades in Africa and Asia reached European livestock in 2026, and whether genetic reassortment — the swapping of genome segments between related viruses — played a role, is still being examined.
• Whether further human cases will appear. Surveillance is now watching for them, and France’s reference laboratory is improving human diagnostics so that a second case, if it occurs, would be found.

The bottom line

Shamonda virus is a sixty-year-old livestock virus that, in October 2026, was documented in a human for the first time, in a severely immunocompromised patient in Lyon who died. French, European and global health authorities agree on the current assessment: an exceptional case, no identified human-to-human transmission, and no identified risk to the general public at this time. There are no treatments and no vaccines. The story to watch is not a looming outbreak — nothing in the evidence supports that framing — but whether surveillance finds a second human case, and what full-genome sequencing says about where the patient’s virus came from. Until then, Shamonda virus is best understood as a warning about how much we still learn from animal surveillance: a virus can circulate for decades, cross a continent, and then, once, cross into a person — and the only reason we know is that someone looked.

Sources

1. World Health Organization. “Shamonda virus” — Questions and Answers. https://www.who.int/news-room/questions-and-answers/item/shamonda-virus (taxonomy: Peribunyaviridae, Orthobunyavirus, Simbu serogroup; first isolated Nigeria 1965; first European detection June 2026; no treatments or vaccines; one human case; brain-related symptoms).
2. Santé publique France. “Shamonda Virus: First Human Case Detected in France — What Do We Know?” https://www.santepubliquefrance.fr/en/news/shamonda-virus-first-human-case-detected-france-what-do-we-know (notified 7 October 2026; Hospices Civils de Lyon; severely immunocompromised; no human-to-human transmission identified; 52 departments, sheep in Oise and Aveyron, horse in Hérault, as of 20 October 2026; diagnostic improvements; One Health investigations).
3. World Organisation for Animal Health (WOAH). “Shamonda virus” disease page and FAQ, last updated 21 October 2026. https://www.woah.org/en/disease/shamonda-virus/ (SHAV-EU1 and SHAV-EU2; animal signs; diagnostics including pan-Simbu PCR, S-segment RT-PCR, serum neutralisation; no commercially available vaccines; little cross-protection from Schmallenberg immunity per Friedrich-Loeffler-Institut; vector-control measures; voluntary reporting).
4. French Ministry of Health and Ministry of Agriculture joint statement, 22 October 2026, as reported by Reuters (22 October 2026) and the European Centre for Disease Prevention and Control statement of the same date (announcement of first human case; “no health risk to the general public identified at this time”; neurological complications “very likely linked” on preliminary findings; midge-bite hypothesis in eastern France; investigations into cause of death and route of infection ongoing; ECDC monitoring and contact with French authorities).
5. Hoffmann B, Scheuch M, Höper D, et al. “Novel orthobunyavirus in cattle, Europe, 2011.” Emerging Infectious Diseases 18(3):469–472, 2012. https://doi.org/10.3201/eid1803.111905 (Schmallenberg virus discovery; adult cattle signs: fever, reduced milk production, diarrhoea).
6. Elliott RM. “Orthobunyaviruses: recent genetic and structural insights.” Nature Reviews Microbiology 12(10):673–685, 2014. https://doi.org/10.1038/nrmicro3332 (tripartite negative-sense RNA genomes; four structural proteins).
7. Yanase T, Kato T, Aizawa M, et al. “Genetic reassortment between Sathuperi and Shamonda viruses of the genus Orthobunyavirus in nature: implications for their genetic relationship to Schmallenberg virus.” Archives of Virology 157(8):1611–1616, 2012. https://doi.org/10.1007/s00705-012-1341-8 (Schmallenberg as a reassortant: M segment from Sathuperi virus, S and L segments from Shamonda virus).
8. Elbers ARW, Loeffen WLA, Quak S, et al. “Seroprevalence of Schmallenberg virus antibodies among dairy cattle, the Netherlands, winter 2011–2012.” Emerging Infectious Diseases 18(7), 2012. https://wwwnc.cdc.gov/eid/article/18/7/12-0323_article (Simbu serogroup; Shamonda isolated from cattle and Culicoides in Nigeria in the 1960s; serosurveys of farmers and veterinarians in Germany and the Netherlands found no Schmallenberg infection).